403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Knight Therapeutics Inc.
(MENAFN- Baystreet) 09:43 AM EST - Knight Therapeutics Inc. : Announced today that Knight's New Drug Submission (NDS) for CREXONT® has been accepted for review by Health Canada. Knight Therapeutics Inc.
shares T are trading unchanged at $6.21.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment